Search results
Author(s):
Stephen Nicholls
Added:
2 months ago
AHA Scientific Sessions 2025 - Phase 1 results show the CRISPR-Cas9 gene editing therapy is a safe treatment option targeting ANGPTL3 in patients with lipid disorders.Prof Stephen Nicholls (Monash Victorian Heart Institute, Clayton, AU) joins us to share results from a first-in-human phase 1 trial investigating a one-time infusion of CTX310, a CRISPR-Cas9 gene editing therapy, at different doses…
View more
Author(s):
Shuo-wen Sun
,
Xing-jie Wang
,
Ruo-chen Yan
,
et al
Added:
9 months ago
Author(s):
Marianna Fontana
Added:
8 months ago
ESC HF 25 - A study investigating CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy demonstrated favourable safety and tolerability, with consistent reductions in serum TTR in both wild-type and variant disease.Prof Marianna Fontana (University College London, UK) joins us to discuss the key findings from a two-part, open-label, phase 1 study investigating the treatment effect,…
View more
Author(s):
Milind Y Desai
Added:
9 months ago
ACC 2025 - First-in-human results from MyPEAK-1 show Tn-201 treatment in adults with Mybpc3-associated hypertropic cardiomyopathy was feasible and safe.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at ACC 2025 to discuss phase Ib/2a results from the first-in-human, non-randomized study investigating the safety and early efficacy of Tn-201, an adeno-associated virus serotype 9 gene…
View more
Dirk Müller-Wieland
Research Area(s) / Expertise:
Job title: Professor of Endocrinology, Metabolism and Diabetes
Author
Author(s):
Camilla Olianti
,
Mauro Giacca
Added:
3 months ago
Author(s):
Wei Gao
,
Hui Wang
,
Jian-long Wang
,
et al
Added:
2 months ago
The Leap Year Gene of Kit McKinley
Added:
1 year ago
Podcast Episode
Author(s):
Tian-le Li
,
Mao-long Fu
,
Li-hong Wang
,
et al
Added:
9 months ago
Author(s):
Nicolas M Van Mieghem
Added:
2 months ago
Stay at the forefront of cardiovascular medicine with our comprehensive video collection from the American Heart Association's Scientific Sessions 2025. Access expert analysis of the most impactful late-breaking trials and featured science shaping clinical practice.Late-Breaker Discussions: Watch Dr Harriette Van Spall break down pivotal clinical trial data and explore its implications for…
View more